Sunitinib in the treatment of thyroid cancer
SM Ferrari, M Centanni, C Virili… - Current medicinal …, 2019 - ingentaconnect.com
Background: Sunitinib (SU11248) is an oral multi-target tyrosine kinase inhibitor (TKI) with
low molecular weight, that inhibits platelet-derived growth factor receptors (PDGF-Rs) and …
low molecular weight, that inhibits platelet-derived growth factor receptors (PDGF-Rs) and …
Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer
Objective Our objective was to evaluate the efficacy and safety of sunitinib following at least
one course of radioactive iodine treatment in patients with advanced differentiated thyroid …
one course of radioactive iodine treatment in patients with advanced differentiated thyroid …
[HTML][HTML] A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data …
A Ravaud, C de la Fouchardière, P Caron… - European Journal of …, 2017 - Elsevier
Purpose Patients with advanced radioactive iodine resistant differentiated (MDTC) or
medullary (MMTC) thyroid cancer had an unmet need. Early data showed promising efficacy …
medullary (MMTC) thyroid cancer had an unmet need. Early data showed promising efficacy …
Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial
6058 Background: There is no standard treatment for advanced thyroid cancer refractory to
radioactive iodine (RTC). There are arguments for implication of angiogenesis in TC …
radioactive iodine (RTC). There are arguments for implication of angiogenesis in TC …
Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma
The limited therapeutic options available for patients with metastatic papillary thyroid
carcinomas (PTC) and follicular thyroid carcinomas (FTC) necessitates the development of …
carcinomas (PTC) and follicular thyroid carcinomas (FTC) necessitates the development of …
Phase 2 study of sunitinib in refractory thyroid cancer
EE Cohen, BM Needles, KJ Cullen, SJ Wong… - Journal of Clinical …, 2008 - ascopubs.org
6025 Background: Few treatment options exist for patients with refractory differentiated
(including papillary, follicular, and Hurthle cell) and medullary thyroid cancers (DTC and …
(including papillary, follicular, and Hurthle cell) and medullary thyroid cancers (DTC and …
Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU
A Ravaud, C Fouchardière, J Asselineau… - The …, 2010 - academic.oup.com
Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate Results of Phase
II THYSU Page 1 Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate …
II THYSU Page 1 Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate …
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period
CD Britten, F Kabbinavar, J Randolph Hecht… - Cancer chemotherapy …, 2008 - Springer
Purpose Sunitinib, an oral multitargeted tyrosine kinase inhibitor that inhibits VEGFR,
PDGFR, FLT3, KIT, and RET, is currently approved for the treatment of imatinib-refractory …
PDGFR, FLT3, KIT, and RET, is currently approved for the treatment of imatinib-refractory …
Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer
MS Fenton, KM Marion, AK Salem, R Hogen, F Naeim… - Thyroid, 2010 - liebertpub.com
Background: Sunitinib malate (Sutent®, Pfizer, Inc.; SU11248) is a selective, multitargeted
inhibitor of receptor tyrosine kinases and has been shown to inhibit receptors for VEGF …
inhibitor of receptor tyrosine kinases and has been shown to inhibit receptors for VEGF …
Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC)
B Goulart, L Carr, RG Martins, K Eaton… - Journal of Clinical …, 2008 - ascopubs.org
6062 Background: There is no standard treatment for metastatic, iodine-refractory, WDTC or
MTC. Thyroid carcinomas are highly vascular tumors, providing a rationale for trials of …
MTC. Thyroid carcinomas are highly vascular tumors, providing a rationale for trials of …